Cellectar Biosciences(CLRB) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Management to host a conference call today at 8:30 am ET FLORHAM PARK, N.J., May 14, 2024 – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2024, and provided a corporate update. First Quarter and Recent Corporate Highlights · Reported a complete remission rate of 64% and overall response ...